96. Crohn disease Clinical trials / Disease details

Clinical trials : 2,442 / Drugs : 1,278 - (DrugBank : 248) / Drug target genes : 142 - Drug target pathways : 209

2 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03681067 (ClinicalTrials.gov)	February 20, 2019	20/8/2018	A Clinical Trial of Antibody GSK1070806 in the Treatment of Patients With Moderate to Severe Crohn's Disease	A Phase Ib/IIb, Randomised, Double Blind, Placebo-Controlled Trial to Investigate the Safety, Tolerability and Clinical Activity of Humanised Antibody GSK1070806 in the Treatment of Patients With Moderate-to-Severe Crohn's Disease	Crohn Disease	Drug: GSK1070806;Drug: Placebo- sodium chloride	University of Birmingham	GlaxoSmithKline;University Hospital Birmingham	Completed	16 Years	N/A	All	5	Phase 1/Phase 2	United Kingdom
2	EUCTR2018-002001-65-GB (EUCTR)	13/12/2018	01/10/2018	A clinical trial of antibody GSK1070806 in the treatment of patients with moderate to severe Crohn’s Disease	A Phase Ib/IIb, Randomised, Double Blind, Placebo-Controlled Trial to Investigate the Safety, Tolerability and Clinical Activity of Humanised Antibody GSK1070806 in the Treatment of Patients with Moderate-to-Severe Crohn’s Disease - CDAID GSK1070806	Crohn's disease MedDRA version: 20.0;Level: LLT;Classification code 10013099;Term: Disease Crohns;System Organ Class: 100000004856 ;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]	Product Name: GSK1070806 INN or Proposed INN: GSK1070806 Other descriptive name: fully humanised, recombinant monoclonal antibody (IgG1)	University of Birmingham	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	36	Human pharmacology (Phase 1): yes Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): no	United Kingdom